GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase 1 study, the addition of GIPR activity to GLP-1R/GCGR co-agonism was reported to greatly potentiate the weight-lowering and glycemic efficacy in overweight subjects (NCT04521738)153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, GIPR agonism within multi-receptor agonists, improves bone metabolism153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, GIP may enhance some of the effects of GLP-1 receptor agonism.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development, and are illustrated by tirzepatide”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“patients with T2DM, while GIP is almost inactive (4).”
BackgroundSelf-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 3×
“Around 1992, Raufman and Eng in New York characterized the Gila monster peptide exendin-4 (18), which turned out to be a full agonist for the GLP-1 receptor (19) (a synthetic version of which, exenatide, reached the market in 2005 (20)).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Indeed, in 2002, mice with a knockout of the GIP receptor were demonstrated to be resistant to the adipogenic effect of a high-fat diet (42), and human genetic studies identified inactivating (Rosenkilde et al, unpublished) mutations in the GIP receptor, which were associated with weight loss (43).”
BackgroundSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“erance—their contribution (via insulin secretion) to postprandial glucose clearance may be as great as to correspond to 80% of the ingested amount of glucose (1).”
Background
Research works printed but not linked: 2
- Stensen S, Gasbjerg LS, Krogh LL, et al. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific effects in obese patients with type 2 diabetes. Diabetologia. 2019; 62: S270- S271.
- Marks V GIP: the obesity hormone. In: James WPT, Parker SW, eds. Current Approaches: Obesity. Southampton, England: Duphar Medical Relations; 1988: 13- 19.
Cited by
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Lister, N. B., Baur, L. A., Felix, J. F., Hill, A. J., Marcus, C., Reinehr, T., Summerbell, C., & Wabitsch, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00435-4 · Cited by 500
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Agonist-induced GIPR desensitization has been proposed as a potential unifying mechanism to explain this paradoxical observation [91,92], raising the fascinating possibility that we may witness the development of competing therapeutic strategies based on either GIPR agonism or antagonism, together with GLP-1R agonism,…”
BackgroundRole of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.01.021 · Cited by 241
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
A review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Whether GIP receptor agonism and antagonism affect energy metabolism via similar or distinct mechanisms and target organs remains to be determined, as well as whether GIP receptor agonism may lead to receptor desensitisation, as previously hypothesised [101].”
BackgroundG protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 197
“Protease-resistant analog of GIP is designed to treat type 2 diabetes mellitus by controlling weight and improving glycaemic control.(545,546) Clinical trials indicate that GIP and GLP-1 analogs exhibit therapeutic effects for neurodegenerative diseases.”
BackgroundMayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Self-citationNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“Nevertheless, a surprising lack of clarity remains about whether the better translational strategy would be to agonize or antagonize the GIP receptor; strong evidence exists that either approach could reduce adiposity and body weight 158,162 .”
BackgroundEfficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
“acting the reductions in potency and there is evidence that if the hyperglycaemia of T2D is reduced to near normal levels by another therapy (eg GLP-1RA) then the insulin-releasing power of GIP is partially restored [9].”
GLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2021) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 103
“They are released in response to food intake and significantly contribute to postprandial insulin secretion and glucose tolerance in individuals with or without T2DM.11,12 Furthermore, GLP-1 delays gastric emptying, promotes satiety, and reduces food intake,13 potentially leading to weight loss.11,14,15 In adults, met…”
BackgroundInfluentialTargeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“One potential theory for this discrepancy 109 focuses on the idea that tirzepatide is highly imbalanced in terms of its agonist activity, with higher potency towards GIPR than GLP1R 110,111 .”
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Su, J., Luo, Y., Hu, S., Tang, L., & Ouyang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713381 · Cited by 127
Novikoff, A., O'Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95
“Recent hypotheses to reconcile these discrepancies include GIPR agonists acting as functional GIPR antagonists, or alternatively that specific ligands engage unique receptor signaling, trafficking, and/or recycling dynamics, commonly referred to as biased-agonism [15].”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationObesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“Due to these findings, GIP did not seem to be a therapeutic option for T2D or obesity (46, 47).”
BackgroundThe incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“GIP does not appear to have any acute effects on food intake in humans,(116) yet discussions are ongoing on the role of GIPR agonists and antagonists as weight loss agents.(117)”
BackgroundSelf-citationMetabolic hormones are integral regulators of female reproductive health and function
Athar, F., Karmani, M., & Templeman, N. M. (2024) · Bioscience Reports · doi:10.1042/bsr20231916 · Cited by 91
“Efforts have now shifted to using GLP-1 receptor agonists [299–301] or dual GIP-and GlP-1-receptor agonists [300,302,303].”
MethodFrías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 70
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
“The synergistic activation of GIP and GLP-1 receptors has been recognized as a promising therapeutic approach in the treatment of T2D and obesity (17, 18).”
BackgroundTaktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 72
“Also, GLP1/GIP receptors antibody fused protein was previously found to improve body weight loss [98].”
BackgroundDual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63
Bastos, R. M. C., Simplício-Filho, A., Sávio-Silva, C., de Oliveira, L. F. V., Cruz, G. N. F., Sousa, E. H., Noronha, I. L., Mangueira, C. L. P., Quaglierini-Ribeiro, H., Josefi-Rocha, G. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073842 · Cited by 70
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 58
“Early evidence revealed that tirzepatide is associated with a significantly positive outcome in controlling both blood glucose and body weight [8].”
BackgroundWang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56
“58 A GLP-1R agonist/GIPR antibody (antagonist) fused protein was reported promoting body weight loss.”
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
“GLP-1 has been exhibited central inhibitory actions on appetite and food intake, comparatively little is seen with the central activity of GIP on appetite [10].”
BackgroundGutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
“The mechanisms underlying the reduction of body weight induced by GIPR antagonism, however, are largely unknown, although some studies suggest that GIPR agonism and antagonism may decrease body weight via similar mechanisms 29 .”
Kizilkaya, H. S., Sørensen, K. V., Kibsgaard, C. J., Gasbjerg, L. S., Hauser, A. S., Sparre-Ulrich, A. H., Grarup, N., & Rosenkilde, M. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749607 · Cited by 52
Self-citationAnson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
“…the primary preventative effect of tirzepatide on time to fi rst major adverse cardiovascular event (MACE), individuals with a history of any of the constituent events were excluded from analysis of the composite outcome. concomitant, or sequential, activation of the two hormone receptors 35 (Fig.”
BackgroundMurty, V. N., Samala, G., Morsy, R. M. I., Mendoza, L. G., Isidro‐Llobet, A., Tom, J. K., Mukherjee, S., Kopach, M. E., & Stockdill, J. L. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10625 · Cited by 45
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“Whereas GLP-1 inhibits appetite and food intake, resulting in weight loss upon chronic administration, long-term GIP therapy generally is generally thought to have no effects on food intake (116).”
Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2022) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 40
Jensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
“The decision to agonize or antagonize GIP, along with the potential molecular mechanisms involved, is the subject of extensive debate in the scienti fi c literature [20 e 23].”
BackgroundSelf-citationGut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Woodward, O. R. M., Gribble, F. M., Reimann, F. M., & Lewis, J. E. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.74301 · Cited by 37
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · Diabetes Care · doi:10.2337/dc21-2166 · Cited by 34
Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 34
Self-citationTang, Y., Zhang, L., Zeng, Y., Wang, X., & Zhang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016639 · Cited by 38
“Glucose-dependent insulinotropic polypeptide (GIP), the other incretin hormone, is similar to GLP-1 and its receptor; however, GIP does not inhibit appetite and food intake (Holst and Rosenkilde, 2020).”
BackgroundRole of bile acids in overweight and obese children and adolescents
Giannini, C., Mastromauro, C., Scapaticci, S., Gentile, C., & Chiarelli, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1011994 · Cited by 32
Aging-related modifications to G protein-coupled receptor signaling diversity
van Gastel, J., Leysen, H., Boddaert, J., Vangenechten, L., Luttrell, L. M., Martin, B., & Maudsley, S. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107793 · Cited by 32
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
“For decades, there has been an interest in GIPR as a therapeutic target in the treatment of type 2 diabetes and obesity (Gasbjerg et al., 2018; Holst & Rosenkilde, 2020; Miyawaki et al., 2002; Nauck, Bartels, et al., 1993).”
Self-citationGoldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
“Obesity NASH GIP controls energy intake remain ambiguous 37,38 and both GIP agonists and antagonists are currently being evaluated for the management of obesity.”
BackgroundEarly combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
“15 Although the effects of the GIP molecule on the pathophysiology of T2D are not fully understood, 16 the dual GIP/GLP-1 RA tirzepatide showed a greater impact than GLP-1 RA on insulin secretion, insulin sensitivity, and weight loss.”
Frumuzachi, O., Rohn, S., & Mocan, A. (2024) · Food Research International · doi:10.1016/j.foodres.2024.115094 · Cited by 33
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“At the same time the effect of GIPR agonism is reduced by increased internalisation and degradation of GIPR, basically creating a direct or functional antagonism of the GIPR [13].”
BackgroundDelvadia, P., Dhote, V. V., Mandloi, A. S., Soni, R., & Shah, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00729 · Cited by 29
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Fénichel, P., Coquillard, P., Brücker-Davis, F., Marchand, P., Cano-Sancho, G., Boda, M., Antignac, J., Iannelli, A., Gugenheim, J., Bizec, B. L., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106400 · Cited by 28
Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety
Garutti, M., Sirico, M., Noto, C., Foffano, L., Hopkins, M., & Puglisi, F. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00604-w · Cited by 35
“Indeed, both the activation and inhibition of GIP receptor appear to induce weight loss [12, 19].”
Guan, R., Yang, Q., Yang, X., Du, W., Li, X., & Ma, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998816 · Cited by 27
“Yet, unlike GLP1, GIP does not inhibit appetite or food intake (Holst and Rosenkilde, 2020), and provides potential protection against hypoglycemia (Christensen et al.”
BackgroundMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 24
“Recent evidence suggests the use of novel dual glucosedependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist play a beneficial role in patients of T2DM (Holst and Rosenkilde, 2020).”
BackgroundThe antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
Glial Modulation of Energy Balance: The Dorsal Vagal Complex Is No Exception
Troadec, J., Gaigé, S., Barbot, M., Lebrun, B., Barbouche, R., & Abysique, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020960 · Cited by 24
Henney, A. E., Riley, D. R. J., Anson, M., Heague, M., Hernandez, G., Alam, U., Craig, S., & Cuthbertson, D. J. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-923oc · Cited by 26
Aronia in the Type 2 Diabetes Treatment Regimen
Christiansen, C., Jeppesen, P. B., Hermansen, K., & Gregersen, S. (2023) · Nutrients · doi:10.3390/nu15194188 · Cited by 26
Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Self-citationLisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
Lok, K.-H., Wareham, N. J., Nair, R. S., How, C. W., & Chuah, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106237 · Cited by 19
Gap junction coupling and islet delta-cell function in health and disease
MIRANDA, C. A., Samad, M., Vergari, E., & Briant, L. J. B. (2021) · Peptides · doi:10.1016/j.peptides.2021.170704 · Cited by 23
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“One widely considered hypothesis is that GIPR agonism results in GIPR desensitization, hence leading to functional GIPR antagonism [105].”
Petrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 18
“As far as preclinical studies are concerned, the findings of rodent studies using GIP(3–30) were generally similar to the ones of human studies [37].”
BackgroundResultReed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“343 The tri-agonist also protected these mice from fasting hyperglycaemia to a greater extent than the coagonist.”
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
“A recent review by Holst elegantly describes this conundrum and presented several possible scenarios focused around GIP receptor desensitisation, internalisation and post receptor signalling recruitment leading to GIP resistance [58].”
BackgroundFerrulli, A., Terruzzi, I., Senesi, P., Succi, M., Cannavaro, D., & Luzi, L. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.02.016 · Cited by 17
He, Q., Chen, B., Wang, G., Zhou, D., Zeng, H., Li, X., Song, Y., Yu, X., Liang, W., Chen, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842879 · Cited by 20
“GLP-1 receptor agonists have been successfully used clinically for T2DM treatment, whereas GIP levels are increased in individuals with obesity and T2DM (Tasyurek et al., 2014; Holst and Rosenkilde, 2020).”
Sharma, A., Blasio, M. J. D., & Ritchie, R. H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15820 · Cited by 14
“Another incretin hormone involved in the regulation of nutrient intake and postprandial metabolic homeostasis is the glucose-dependent insulinotropic peptide (GIP) (Holst & Rosenkilde, 2020).”
BackgroundInfluentialChu, L., Terasaki, M., Mattsson, C. L., Teinturier, R., Charbord, J., Dirice, E., Liu, K., Miskelly, M. G., Zhou, Q., Wierup, N., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.001 · Cited by 16
Gadgaard, S., Windeløv, J. A., Schiellerup, S. P., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114383 · Cited by 17
Self-citationBoutari, C., Stefanakis, K., Simati, S., Guatibonza-García, V., Valenzuela‐Vallejo, L., Anastasiou, I. A., Connelly, M. A., Kokkinos, A. D., & Mantzoros, C. S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02264-5 · Cited by 17
“GIP, an incretin promoter of postprandial insulin secretion alongside GLP-1 has been frequently implicated in glucose homeostasis [67, 68] and is being leveraged for the treatment of metabolic disease [69].”
BackgroundNewsholme, P., Rowlands, J., Rose’Meyer, R. B., & Cruzat, V. F. (2022) · Antioxidants · doi:10.3390/antiox11010108 · Cited by 16
“When monotherapy fails to control hyperglycaemia, agents with different pharmacological actions are combined to control blood glucose levels in T2DM patients and prevent chronic hyperglycaemia and the development of comorbid macro and microvascular diseases.”
BackgroundInfluentialAkindehin, S., Liśkiewicz, A., Liśkiewicz, D., Bernecker, M., García‐Cáceres, C., Drucker, D. J., Finan, B., Grandl, G., Gutgesell, R. M., Hofmann, S. M., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101915 · Cited by 17
Kamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70032 · Cited by 23
“However, similar results have not been seen with other GLP‐1/GIP dual agonists that have not produced the same results as tirze-patide [61].”
Bhushan, B., Granata, D., Kaas, C. S., Kasimova, M. A., Ren, Q., Cramer, C. N., White, M. D., Hansen, A. M. K., Fledelius, C., Invernizzi, G., et al. (2022) · Chemical Science · doi:10.1039/d1sc06844j · Cited by 16
Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 16
“…1970 s. [14–20] For detailed information on the serendipity discovery of GIP and its functional studies, please see nice review articles and other publications elsewhere, [21–23] including the “In Memoriam” composed by Timothy Kieffer (a formal PhD student of late professor John Brown) in 2017.”
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Bakhtiari, M., & Asadipooya, K. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220104103325 · Cited by 11
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Al‐Zaid, B., Chacko, S., Ezeamuzie, C. I., Bünemann, M., Krasel, C., Karimian, T., Lanzerstorfer, P., & Al‐Sabah, S. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1013 · Cited by 10
Al-Sabah, S. K., Al‐Khairi, I., Jamal, M. H., Qaddoumi, M. G., Al-Ajmi, F. A., Kumar, J., ABUKHALAF, N. A., Cherian, P., Madhu, D., Arefanian, H., et al. (2024) · Medical Principles and Practice · doi:10.1159/000540534 · Cited by 14
“The bene fi ts of GIP, independent of GLP-1, have been con-fi rmed in vivo, and these include protection against β -cell apoptosis, increased pancreatic and β -cell area, and increased insulin content, suggesting that these two in-cretins may have speci fi c and complimentary roles [12, 13].”
Background
Metadata
- Authors
- Holst, J. J., & Rosenkilde, M. M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens Juul
- Rosenkilde, Mette Marie
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-05-27
- Volume
- 105
- Issue
- 8
- Pages
- e2710-e2716
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7308078
- OpenAlex
- W3030023482
- Cited by
- 207
- References
- 60
- Citations by year
- 2026: 32 · 2025: 36 · 2024: 39 · 2023: 28 · 2022: 40 · 2021: 26 · 2020: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, type 2 diabetes, obesity, GIP receptor antagonist, receptor internalization, ligand structure, insulin secretion, weight loss treatment, receptor signaling
- MeSH terms
- Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.